Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-03-09
1997-04-08
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514331, A61K 31445
Patent
active
056188242
ABSTRACT:
The present invention is directed to 5-HT.sub.2 antagonists and their use as agents in the treatment of obsessive-compulsive disorders (OCD). The invention is particularly directed to the compound (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidine methanol which is a member of a class of 5-HT.sub.2 antagonists known as N-aralkyl piperidinemethanol derivatives which are potent and selective inhibitors of the binding of serotonin at the 5-HT.sub.2 receptor site.
REFERENCES:
patent: 4783471 (1988-11-01), Carr et al.
patent: 5288749 (1994-02-01), Meyer et al.
patent: 5296491 (1994-03-01), Shutske et al.
patent: 5326768 (1994-07-01), van Wijngaarden et al.
patent: 5441961 (1995-08-01), Cohen et al.
Lucey, J.V. et al., Int. Clin. Psychopharmacol., vol. 7, No. 1, 1992-pp. 45-49.
Sorenson, S.M. et al., J. Pharmacol. Exp. Ther., vol. 266, No. 2, Aug. 1993, pp. 684-691.
Schreiber et al., Eur. J. Pharmacol., vol. 264, No. 1, 13 Oct. 1994.
Swerdlow, Neal R. Behavioral and Brain Sciences, (1987) 10, 197-245.
Baxter, Lewis R. Jr. et al., Arch Gen Physhiatry, vol. 44, Mar. 1987, pp. 211-218.
Rapoport, Judith L. M.D. et al., Phychopharmacology Bulletin, vol. 24, No. 3, 1988, pp. 380-384.
Bastani Bijan et al., Arch Gen Physhiatry, vol. 47, Sep. 1990. pp. 833-839.
Benkelfat, Chawki et al., Arch Gen Physhiatry, vol. 47, Sep. 1990. pp. 840-848.
Swerdlow, N.R. et al., Psychopharmacology, (1992) 108: 189-195.
Swerdlow N.R. et al., Journal of Psychopharmacology, 6(2) (1992) 176-190.
Swerdlow, N.R. et al., Biol Psychiatry, 1993, 33: pp. 298-301.
Kehne, John H. et al., The Journal of Pharmacology and Experimental Therapeutics, vol. 260, No. 1, pp. 78-89, 1990.
Murphy, David M.D., Neuropsychopharmacology, 1990, vol. 3, No. 56, pp. 457-471.
Padich, Robert A., "Text Related to Serotonin and Obsessive Compulsive Disorder" Abstract of Dissertation on file with the Un. of Cincinnati (Summer 1993).
Kehne John H.
Padich Robert A.
Schmidt Christopher J.
Cintins Marianne M.
Jarvis William R.A.
Merrell Pharmaceuticals Inc.
Sayles Michael J.
LandOfFree
Treatment of obsessive-compulsive disorders with 5-HT.sub.2 anta does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of obsessive-compulsive disorders with 5-HT.sub.2 anta, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of obsessive-compulsive disorders with 5-HT.sub.2 anta will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2397960